Advertisement
Singapore markets close in 4 hours 33 minutes
  • Straits Times Index

    3,173.12
    +1.19 (+0.04%)
     
  • Nikkei

    39,734.96
    -5.44 (-0.01%)
     
  • Hang Seng

    16,550.90
    -186.20 (-1.11%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Bitcoin USD

    65,421.05
    -2,503.68 (-3.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.66 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Gold

    2,165.40
    +1.10 (+0.05%)
     
  • Crude Oil

    82.72
    0.00 (0.00%)
     
  • 10-Yr Bond

    4.3400
    -4.3400 (-100.00%)
     
  • FTSE Bursa Malaysia

    1,549.49
    -4.15 (-0.27%)
     
  • Jakarta Composite Index

    7,341.01
    +38.56 (+0.53%)
     
  • PSE Index

    6,894.40
    +41.11 (+0.60%)
     

How Analysts Rate Regenxbio and Peers in April 2018

How Analysts Rate Regenxbio and Peers in April 2018

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).